cgp 12177 and cilostamide

cgp 12177 has been researched along with cilostamide in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's3 (75.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Era, S; Izawa, T; Komabayashi, T; Suda, K; Tsuboi, M1
Hernandez, J; Kaumann, AJ; Vargas, ML1
Kaumann, A; Molenaar, P; Semmler, AB1
Galindo-Tovar, A; Kaumann, AJ; Vargas, ML1

Other Studies

4 other study(ies) available for cgp 12177 and cilostamide

ArticleYear
Effect of insulin on adipocyte lipolysis in exercise-trained rats.
    Journal of applied physiology (Bethesda, Md. : 1985), 1993, Volume: 74, Issue:6

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adipose Tissue; Adrenergic beta-Antagonists; Animals; Binding, Competitive; In Vitro Techniques; Insulin; Lipolysis; Male; Norepinephrine; Physical Conditioning, Animal; Propanolamines; Quinolones; Rats; Rats, Wistar; Receptors, Adrenergic, beta

1993
Phosphodiesterase PDE3 blunts the positive inotropic and cyclic AMP enhancing effects of CGP12177 but not of noradrenaline in rat ventricle.
    British journal of pharmacology, 2006, Volume: 147, Issue:2

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic beta-1 Receptor Agonists; Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Heart Ventricles; In Vitro Techniques; Male; Myocardial Contraction; Myocardium; Norepinephrine; Propanolamines; Quinolones; Rats; Rats, Sprague-Dawley; Rolipram; Stimulation, Chemical; Ventricular Function

2006
The effects of both noradrenaline and CGP12177, mediated through human beta1 -adrenoceptors, are reduced by PDE3 in human atrium but PDE4 in CHO cells.
    Naunyn-Schmiedeberg's archives of pharmacology, 2007, Volume: 375, Issue:2

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic beta-Agonists; Aged; Animals; Atrial Appendage; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Synergism; Female; Humans; Isometric Contraction; Isoproterenol; Male; Middle Aged; Norepinephrine; Phosphodiesterase Inhibitors; Propanolamines; Quinolones; Receptors, Adrenergic, beta-1; Rolipram; Signal Transduction

2007
Phosphodiesterases PDE3 and PDE4 jointly control the inotropic effects but not chronotropic effects of (-)-CGP12177 despite PDE4-evoked sinoatrial bradycardia in rat atrium.
    Naunyn-Schmiedeberg's archives of pharmacology, 2009, Volume: 379, Issue:4

    Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-Agonists; Animals; Arrhythmia, Sinus; Atrial Function, Left; Atrial Function, Right; Bradycardia; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Partial Agonism; Female; Heart Atria; Heart Rate; In Vitro Techniques; Isoproterenol; Male; Myocardial Contraction; Phosphodiesterase 3 Inhibitors; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Propanolamines; Quinolones; Rats; Rats, Sprague-Dawley; Rolipram; Stimulation, Chemical; Tachycardia

2009